GLP1R and chronic kidney disease: Patients treated with SGLT2i were less likely to be diagnosed with new CKD over a 5-year period post initiation compared with the GLP-1 RA cohort (RR 0.49 [95% CI 0.28, 0.86] p=0.0118).